Abstract
Twenty-five CD4+ cytotoxic T lymphocyte (CTL) clones were obtained from the peripheral blood or tumor tissues of melanoma patients undergoing active specific immunotherapy. Melanoma-reactive T cells were cloned by limiting dilution using either autologous or allogeneic melanoma cells to stimulate their proliferation. Sixteen of the clones reacted against autologous melanoma cells but not against the autologous lymphoblastoid cell line, which we defined as “melanoma-specific”. Optimal demonstration of the lytic activity of CD4+ CTL required a 16-h incubation period and an effector∶target cell ratio of 40∶1. In addition, a 24-h pre-incubation of the target melanoma cells with 100 U interferon (IFN)γ consistently augmented lysis by these CD4+ CTL, increasing it from a mean level of 20% to one of 52%. Lysis by 8 of the 11 melanoma-reactive CD4+ T cell clones was exclusively HLA-class-I-restricted, as judged by blocking with monoclonal antibodies (mAb). Five of these HLA class-I-restricted clones were reactive only with the autologous melanoma cells, while the other 3 clones were also reactive with allogeneic melanoma cells. In all cases, the T cells and melanoma targets shared at least one HLA class I allele, usually HLA-A2, HLA-C3 or HLA-B62. Interestingly, lysis by 2 of the 11 clones was inhibited by both anti-HLA-class-I or -HLA-class-II mAb, while lysis by 1 other clone was inhibited by neither. HLA class I molecules and several accessory molecules were maximally expressed by the melanoma target cells, both in terms of distribution and copy number before IFNγ treatment. Thus, IFNγ may have acted by increasing the expression of melanoma-associated epitopes as presented by HLA class I (or HLA class II) molecules. A proportion of human CD4+CTL appeared to recognize melanoma-associated epitopes presented by the HLA class I molecule, although their lytic potency may be less than that of their CD8+ counterparts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bank I, Chess L (1985) Perturbation of the T4 molecule transmits a negative signal to T cells. J Exp Med 162: 1294
Basham TY, Merigan TC (1983) Recombinant interferon-γ increase HLA-DR synthesis and expression. J Immunol 130: 1492
Carrel S, Schmidt-Kessen A, Giuffre L (1985) Recombinant interferon-γ can induce the expression of HLA-DR and -CD on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor associated antigens. Eur J Immunol 15: 118
Chang JC, Moorhead JW (1986) Hapten-specific, class II-restricted killing by cloned T cells: direct lysis and production of a cytotoxic factor. J Immunol 136: 2826
Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, Strominger JL (1992) Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358: 764
Davis MM, Bjorkman PJ (1989) A model for T cell receptor and MHC/peptide interaction. Adv Exp Med Biol 254: 13
Erb P, Grogg D, Troxler M, Kennedy M, Fluri M (1990) CD4+ T cell-mediated killing of MHC class II-positive antigen-presenting cells. I. Characterization of target cell recognition by in vivo or in vitro activated CD4+ killer T cells. J Immunol 144: 790
Giacomini P, Imberti L, Aguzzi A, Fisher PB, Trinchieri G, Ferrone S (1985) Immunochemical analysis of the modulation of human melanoma associated antigens by DNA recombinant immune interferon. J Immunol 135: 2887
Harel W, Goedegebuure PS, LeMay LG, Huang XQ, Kan-Mitchell J, Mitchell MS (1993) Specificity of cloned cytolytic T cells from actively immunized melanoma patients. Vaccine Res 2: 41
Hersey P (1993) Vaccinia viral lysates in treatment of melanoma. In: Mitchell MS (ed) Biomodulation: a new approach to cancer treatment. Mc Graw-Hill, pp 302
Houghton AN, Cordon-Cardo C, Eisinger M (1986) Differentiation antigens of melanoma and melanocytes. Int Rev Exp Pathol 28: 217
Jacobson S, Richert JB, Biddison WE, Satinsky A, Harztmann RJ, McFarland HF (1984) Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol 133: 754
Janeway Jr CA (1989) The role of CD4 in T-cell activation: accessory molecule or co-receptor? Immunol Today 10: 234
Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC (1991) Identification of self peptides bound to purified HLA-B27. Nature 353: 326
Kan-Mitchell J, Liggett PE, Harel W, Steinman L, Nitta T, Oksenberg JR, Posner MR, Mitchell MS (1991) Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother 33: 333
Kan-Mitchell J, Huang XQ, Steinman L, Oksenberg JR, Harel W, Parker JW, Goedegebuure PS, Darrow TL, Mitchell MS (1993) Clonal analysis of in vivo-activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother (in press)
Kaplan DR, Griffith R, Braciale VL, Braciale TJ (1984) Influenza virus-specific human cytotoxic T cell clones: heterogeneity in antigenic specifity and restriction by class II MHC products. Cell Immunol 88: 193
Kelly A, Powis SH, Glynne R, Radley N, Beck S, Trowsdale J (1991) Second proteasome-related gene in the human MHC class II region. Nature 353: 667
Mitchell MS (1991) Attempts to optimize active specific immunotherapy for melanoma. Int Rev Immunol 7: 331
Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883
Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L (1990) Active-specific immunotherapy for melanoma. J Clin Oncol 8: 856
Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216: 463
Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma II. Mechanism of induction and specificity of suppresion. J Immunol 136: 1893
Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169: 1961
Nistico P, Tecce R, Giacomini P, Cavallari A, D'Agnano I, Fisher PB, Natali PG (1990) Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 50: 7422
Ortiz-Navarrete V, Seelig A, Gernold M, Frentzel S, Kloetzel PM, Hammerling GJ (1991) Subunit of the ‘20S’ proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 353: 662
Platsoucas CD (1991) Human autologous tumor-specific T cells in malignant melanoma. Cancer Metastasis Rev 10: 151
Rosenberg SA (1990) The immunotherapy of human cancer: from laboratory to bedside. In: Lotze MT, Finn OJ (eds) Cellular immunity and the immunotherapy of cancer. Wiley-Liss, New York, p 383
Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318
Shu S, Chou T, Sakai K (1989) Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143: 740
Somasundaram R, Sperlagh M, Adachi K, Zell T, Guerry D, Herlyn D (1991) Human cytolytic T-lymphocyte clones for autologous malignant melanoma. Proc Am Assoc Cancer Res 32: 245
Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptibility to lysis. II. evaluation of tumor infiltrating lymphocytes. J Immunol 142: 1767
Vanky F, Stuber G, Rotstein S, Klein E (1989) Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells. Cancer Immunol Immunother 28: 17
Author information
Authors and Affiliations
Additional information
This work was supported by USPHS grant R01-CA 36233, and a grant from the Concern Foundation for Cancer Research.
Rights and permissions
About this article
Cite this article
LeMay, L.G., Kan-Mitchell, J., Goedegebuure, P. et al. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-γ. Cancer Immunol Immunother 37, 187–194 (1993). https://doi.org/10.1007/BF01525434
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01525434